A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma

Published:2022-07-19 Issue:10 Volume:63 Page:2503-2506
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Zhang Qingyuan¹,Tao Rong²,Li Zhenyu³,Guo Haiyi⁴,Ji Meng⁵,Zhang Lu⁴,Huang Jane⁶,Lina Fu⁵^ORCID,Zhong Jinhua⁴,Zhou Jianfeng⁷

Affiliation:

1. Department of Internal Medicine-Oncology, Cancer Hospital of Harbin Medical University, Harbin, China

2. Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

3. The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

4. BeiGene (Shanghai) Co., Ltd, Shanghai, China

5. BeiGene (Beijing) Co., Ltd, Beijing, China

6. BeiGene USA, Inc, San Mateo, CA, USA

7. Tongji Hospital, Tongji Medical College, Wuhan, China

Funder

BeiGene (Beijing) Co., Ltd.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2074985

Reference19 articles.

1. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

2. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

3. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

4. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

5. Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3